Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: LoLoLoLita who wrote (3913)	5/5/1998 6:14:00 AM
From: Mr Logic	Read Replies (2) \| Respond to of 7041

David, >>So this is your research? It's apples and oranges.<< Could you explain what you mean by this? Aren't Viagra and Vasomax both supposed to be Oral ED treatments? Why isn't it reasonable to make the broad comparison as CR did? Thanks.

To: LoLoLoLita who wrote (3913)	5/5/1998 12:31:00 PM
From: CalculatedRisk	Read Replies (1) \| Respond to of 7041

David, just a start. This information is from publicly available sources. Actually this presentation is biased towards Vasomax for the following reasons: 1) Viagra's study group was significantly broader and included more difficult patients. The study group was also much larger. 2) The criteria for efficacy appears more difficult for Viagra. Vasomax just required showing a certain amount of "improvement". 3) Dropout rates were very low for Viagra (about the same as for a placebo ... around 2.5%). Dropout rates were not reported for Vasomax on the poster session. Regards, Bill